Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rimeporide SCHEMBL30309010 | 1.00 | SLC9A1 (1.00) | SLC9A1 | |
| Rimeporide SCHEMBL1022632 | 0.98 | SLC9A1 (0.97) | SLC9A1 | |
| Rimeporide SCHEMBL29406681 | 0.98 | SLC9A1 (0.97) | SLC9A1 | |
| Rimeporide SCHEMBL16712399 | 0.98 | SLC9A1 (0.97) | SLC9A1 | |
| Rimeporide SCHEMBL1020614 | 0.97 | SLC9A1 (0.94) | SLC9A1 | |
| SCHEMBL8531009 | 0.92 | SLC9A1 (0.85) | SLC9A1 | |
| SCHEMBL6932529 | 0.91 | SLC9A1 (0.83) | SLC9A1 | |
| SCHEMBL6935169 | 0.91 | SLC9A1 (0.83) | SLC9A1 | |
| SCHEMBL6935053 | 0.91 | SLC9A1 (0.83) | SLC9A1 | |
| SCHEMBL8441506 | 0.90 | SLC9A1 (0.82) | SLC9A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2671576-B1 | Pharmaceutical composition for treating diseases associated with insulin resistance and ß-cell dysfunction | MERCK PATENT GMBH (DE) | 2020-04-08 | — | — | EP | claimed |
| US-10292949-B2 | Pharmaceutical composition comprising rimeporide for treating diseases associated with insulin resistance and β-cell dysfunction | MECK PATENT GMBH (DE) | 2019-05-21 | — | — | US | claimed |
| US-20170189354-A1 | PHARMACEUTICAL COMPOSITION COMPRISING RIMEPORIDE FOR TREATING DISEASES ASSOCIATED WITH INSULIN RESISTANCE AND BETA-CELL DYSFUNCTION | MERCK PATENT GMBH (DE) | 2017-07-06 | — | — | US | claimed |
| EP-2271327-B1 | Pharmaceutical composition comprising rimeporide for treating diseases associated with beta-cell dysfunction | MERCK PATENT GMBH (DE) | 2015-05-20 | — | — | EP | claimed |
| EP-2671576-A1 | Pharmaceutical composition for treating diseases associated with insulin resistance and ß-cell dysfunction | Merck Patent GmbH (DE) | 2013-12-11 | — | — | EP | claimed |
| US-20110060051-A1 | PHARMACEUTICAL COMPOSITION COMPRISING RIMEPORIDE FOR TREATING DISEASES ASSOCIATED WITH INSULIN RESISTANCE AND BETA-CELL DYSFUNCTION | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-03-10 | — | — | US | claimed |
| EP-2271327-A1 | PHARMACEUTICAL COMPOSITION COMPRISING RIMEPORIDE FOR TREATING DISEASES ASSOCIATED WITH INSULIN RESISTANCE AND BETA-CELL DYSFUNCTION | Merck Patent GmbH (DE) | 2011-01-12 | — | — | EP | claimed |
| WO-2009135583-A1 | PHARMACEUTICAL COMPOSITION COMPRISING RIMEPORIDE FOR TREATING DISEASES ASSOCIATED WITH INSULIN RESISTANCE AND BETA-CELL DYSFUNCTION | MERCK PATENT GMBH (DE) | 2009-11-12 | — | — | WO | claimed |
| US-20070299139-A1 | Lyophilisate Comprising N-Diaminomethylene-2-Methyl-4,5-Di(Methylsulfonyl)Benzamide | MERCK PATENT GMBH (DE) | 2007-12-27 | — | — | US | claimed |
| EP-1791528-A1 | LYOPHILISATE CONTAINING N-DIAMINOMETHYLENE-2-METHYL-4,5-DI-(METHYLSULFONYL)-BENZAMIDE | Merck Patent GmbH (DE) | 2007-06-06 | — | — | EP | claimed |
| WO-2006032386-A1 | LYOPHILISATE CONTAINING N-DIAMINOMETHYLENE-2-METHYL-4,5-DI-(METHYLSULFONYL)-BENZAMIDE | MERCK PATENT GMBH (DE) | 2006-03-30 | — | — | WO | claimed |
| EP-1098866-B1 | METHOD FOR PRODUCING ORTHO-ALKYLATED BENZOIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2004-02-11 | — | — | EP | claimed |
| EP-0758644-B1 | Sulfonyl- or sulfinyl-benzoyl-guanidine derivatives | MERCK PATENT GMBH (DE) | 2003-10-15 | — | — | EP | claimed |
| US-6573404-B2 | Intermediates in industrial organic synthesis, e.g. in the preparation of fine chemicals, dyes and crop-protection compositions | MERCK PATENT GMBH (DE) | 2003-06-03 | — | — | US | claimed |
| US-20030069444-A1 | METHOD FOR PRODUCING ORTHO-ALKYLATED BENZOIC ACID DERIVATIVES | MERCK KGAA (DE) | 2003-04-10 | — | — | US | claimed |
| JP-2002521352-A | — | — | 2002-07-16 | — | — | JP | claimed |
| US-20020091286-A1 | Method for producing ortho-alkylated benzoic acid derivatives | MERCK GMBH (DE) | 2002-07-11 | — | — | US | claimed |
| EP-1098866-A1 | METHOD FOR PRODUCING ORTHO-ALKYLATED BENZOIC ACID DERIVATIVES | MERCK PATENT GmbH (DE) | 2001-05-16 | — | — | EP | claimed |
| WO-2000005187-A1 | METHOD FOR PRODUCING ORTHO-ALKYLATED BENZOIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2000-02-03 | — | — | WO | claimed |
| EP-0758644-A1 | Sulfonyl- or sulfinyl-benzoyl-guanidine derivatives | MERCK PATENT GmbH (DE) | 1997-02-19 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091286-A1 | Method for producing ortho-alkylated benzoic acid derivatives | AOC2, OXER1, GABBR2 | SLC9A1 2216/4885 |
| US-20030069444-A1 | METHOD FOR PRODUCING ORTHO-ALKYLATED BENZOIC ACID DERIVATIVES | AOC2, OXER1, GABBR2 | SLC9A1 2216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.